Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national
8
×
national blog main
national top stories
boston blog main
boston top stories
san francisco blog main
biotech
gene therapy
new york blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
cancer
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
car-t
celgene
crispr
pfizer
sanofi
spark therapeutics
biogen
biomarin pharmaceutical
What
gene
8
×
therapy
bio
roundup
drug
advanced
aren’t
car
crispr
fda
moves
new
patients
prices
science
access
alnylam’s
alzheimer’s
approval
becker
bff
billions
cancer
capacity
cas
cell
cells
chemistry
cmc
companies
conference
consistent
consolidation
controls
cutting
deals
defect
developers
devoted
different
Language
unset
Current search:
national
×
gene
×
@xconomy.com
4 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
6 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”